Catalent Inc (NYSE:CTLT) insider Barry Littlejohns sold 47,265 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $41.64, for a total value of $1,968,114.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
CTLT traded down $0.14 during trading on Friday, reaching $37.51. The stock had a trading volume of 1,133,400 shares, compared to its average volume of 857,435. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.24 and a beta of 1.45. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.79. Catalent Inc has a 1-year low of $34.24 and a 1-year high of $47.87.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company had revenue of $551.80 million during the quarter, compared to the consensus estimate of $582.44 million. During the same quarter in the prior year, the firm earned $0.21 EPS. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts expect that Catalent Inc will post 1.72 EPS for the current fiscal year.
A number of equities analysts recently issued reports on CTLT shares. TheStreet lowered Catalent from a “b-” rating to a “c+” rating in a report on Wednesday. Royal Bank of Canada set a $44.00 price objective on Catalent and gave the stock a “buy” rating in a report on Wednesday. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research raised Catalent from a “sell” rating to a “hold” rating in a report on Monday, October 1st. Finally, First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and decreased their price objective for the stock from $47.00 to $43.00 in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Catalent presently has an average rating of “Buy” and an average price target of $48.11.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.